Integrins and vascular extracellular matrix assembly

Journal of Clinical Investigation

Volumn 99, Issue 6, 1997, Pages 1149-1152

  Ruoslahti, Erkki ^a   Engvall, Eva ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; COLLAGEN TYPE 1; FIBRONECTIN; INTEGRIN; LAMININ; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL INJURY; CANCER INHIBITION; CELL ADHESION; CELL INTERACTION; CELL PROTECTION; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030944931     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119269     Document Type: Review

References (37)

1. Hynes, R.O. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:11-25.
2. Ruoslahti, E. 1996. RGD and other recognition sequences for integrins. Ann. Rev. Cell Dev. Biol. 12:697-715.
3. Delcommenne, M., and C.H. Streuli. 1995. Control of integrin expression by extracellular matrix. J. Biol. Chem. 270:26794-26801.
4. Mosher, D.F. 1993. Assembly of fibronectin into extracellular matrix. Curr. Opin. Struc. Biol. 3:214-222.
5. Conforti, G., C. Dominguez-Jiminez, A. Zanetti, M.A. Gimbrone, O. Cremona, P.C. Marchisio, and E. Dejana. 1992. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood. 80: 437-446.
6. Liaw, L., M.P. Skinner, E.W. Raines, R. Ross, D.A. Cheresh, S.M. Schwartz, and C.M. Giachelli. 1995. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. J. Clin. Invest. 95:713-724.
7. Hynes, R.O. 1996. Targeted mutations in cell adhesion genes: What have we learned from them? Dev. Biol. 180:402-412.
8. Kratochwil, K., M. Dziadek, J. Lohler, K. Harbers, and R. Jaenisch. 1986. Normal epithelial branching morphogenesis in the absence of collagen I. Dev. Biol. 117:596-606.
9. Seiffert, D., K. Crain, N.V. Wagner, and D.J. Loskutoff. 1994. Vitronectin gene expression in vivo. J. Biol. Chem. 269:19836-19842.
10. Jucker, M., M. Tian, D.D. Norton, C. Sherman, and J.W. Kusiak. 1996. Laminin alpha 2 is a component of brain capillary basement membrane: reduced expression in dystrophic dy mice. Neuroscience. 71:1133-1161.
11. Engvall, E., and U. Wewer. 1996. Domains of laminin. J. Cell. Biochem. 61:493-501.
12. Noakes, P.G., J.H. Miner, M. Guatam, J.M. Cunningham, J.R. Sanes, and J.P. Merlie. 1995. The renal glomerulus of mice lacking s-laminin/laminin beta 2: nephrosis despite molecular compensation by laminin beta 1. Nat. Genet. 10:400-406.
13. Tryggvason, K. 1995. Molecular properties and diseases of collagens. Kidney Int. Suppl. 49:S24-S28.
14. Ljubimov, A.V., R.E. Burgeson, R.J. Butkowski, J.R. Couchman, R.R. Wu, Y. Ninomiya, Y. Sado, E. Maguen, A.B. Nesburn, and M.C. Kenney. 1996. Extracellular matrix alterations in human corneas with bullous keratopathy. Invest. Ophthalmol. Vis. Sci. 37:997-1007.
15. Hynes, R.O., and D. Wagner. 1996. Genetic manipulation of vascular adhesion molecules in the mouse. J. Clin. Invest. 98:2193-2195.
16. Ruggeri, Z.M. 1997. von Willebrand factor. J. Clin. Invest. 97:559-564.
17. Dietz, H.D., and R.E. Pyeritz. 1995. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum. Mol. Genet. 4:799-809.
18. Reinhardt, D.P., R.N. Ono, and L. Sakai. 1997. Calcium stabilizes fibrillin-1 against protcolytic degradation. J. Biol. Chem. 272:1231-1236.
19. Steinman, B., P.M. Royce, and A. Superti-Furga. 1993. The Ehlers-Danlos syndrome. In Connective Tissue and Its Heritable Disorders: Molecular, Genetic and Medical Aspects. P.M. Royce and B. Steinman, editors. Wiley-Liss, New York. 351-407.
20. Curran, M.E., D.L. Atkinson, A.K. Ewart, C.A. Morris, M.F. Leppert, and M.T. Keating. 1993. The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. Cell. 73:159-168.
21. Coller, B. 1997. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor in therapeutics. J. Clin. Invest. In press.
22. Choi, E.T., L. Engel, A.D. Callow, S. Sun, J. Trachtenberg, S. Santoro, and U.S. Ryan. 1994. Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA. J. Vasc. Surg. 19: 125-134.
23. Assoian, R., and G. Marcantonio. 1996. The relationship between cell adhesion and growth. J. Clin. Invest. 98:2436-2439.
24. Wu, C., P.E. Hughes, M.H. Ginsberg, and J.A. McDonald. 1996. Identification of a new biological function for the integrin αvβ3: initiation of fibronectin matrix assembly. Cell Adhes. Commun. 4:149-158.
25. Yao, L.Y., C. Moody, E. Schönherr, T.N. Wight, and L.J. Sandell. 1994. Identification of the proteoglycan versican in aorta and smooth muscle cells by DNA sequence analysis, in situ hybridization and immunohistochemistry. Matrix Biol. 14:213-225.
26. Wolf, Y.G., L.M. Rasmussen, and E. Ruoslahti. 1994. Antibodies against transforming growth factor β-1 suppress intimal hyperplasia in a rat model. J. Clin. Invest. 93:1172-1178.
27. Border, W.A., and N.A. Noble. 1994. Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331:1286-1292.
28. Butcher, E.C. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 67:1033-1036.
29. Pasqualini, R., and E. Ruoslahti. 1996. Organ targeting in vivo using phage display peptide libraries. Nature (Lond.). 380:364-366.
30. Brooks ,P.C., M.P. Montgomery, M. Rosenfeld, R.A. Feisfeld, T. Hu, G. Klier, and D.A. Cheresh. 1994. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1157-1164.
31. Hammes, H.-P., M. Brownlee, A. Jonczyk, A. Sutter, and K.T. Preissner. 1996. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits neovascularization. Nat. Med. 2:529-533.
32. Brooks, P.C., S. Strömblad, R. Klemke, D. Visscher, F.H. Sarkar, and D.A. Cheresh. 1995. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96:1815-1822.
33. Friedlander, M., C.L. Theesfeld, M. Sugita, M. Fruttiger, M.A. Thomas, S. Chang, and D.A. Cheresh. 1996. Involvement of integrins alphavbeta3 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA. 93:9764-9769.
34. 1 integrin supports survival of cells on fibronectin and upregulates Bcl-2 expression. Proc. Natl. Acad. Sci. USA. 92:6161-6165.
35. Carnemolla, B., D. Neri, P. Castellani, A. Leprini, G. Neri, A. Pini, G. Winter, and L. Zardi. 1996. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer. 68:397-405.
36. Bornstein, P. 1995. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol. 130:503-506.
37. O'Reilly, M.S., T. Boehm, Y. Shing, N. Fukai, G. Vasios, W.S. Lane, E. Flynn, J.R. Birkhead, B.R. Olsen, and J. Folkman. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277-285.